MRI evaluation of primary chemotherapy response in breast cancer;Évaluation par IRM de la réponse à la chimiothérapie d'induction dans les cancers du sein

Bulletin du Cancer

Volumn 91, Issue 9, 2004, Pages 721-728

  Vénat Bouvet, Laurence ^a   Desfougères, Michèle ^a   Aubard, Y ^a   Mollard, J ^a   Fermeaux, V ^a   Genet, D ^a   Labourey, J L ^a   Martin, J ^a   Lebrun Ly, V ^a   Maubon, Antoine ^a   Tubiana Mathieu, N ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Breast cancer; Breast MRI; Neoadjuvant chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MEDICAL EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT INFORMATION; PHYSICAL EXAMINATION; REVIEW; TISSUE SECTION; ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; EVALUATION; LUNG CARCINOMA; MINIMAL RESIDUAL DISEASE; PAGET NIPPLE DISEASE; PATHOLOGY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM, RESIDUAL;

EID: 6344260069     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Early Breast Cancer Trialist Collaborative Group. Polychemotherapy for early breast cancer : an overview of the randomised trials. Lancet 1998 ; 352 : 930-42.
2. Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol 2000 ; 18 : 1558-69.
3. Mauriac L, Durand M, Avril A, Dilhuydy JM. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable rumors larger rhan 3 cm. Results of a randomized trial in a single centre. Ann Oncol 1991 ; 2 : 347-54.
4. Powles TJ, Hickish TF, Makris A, Ashley SEMEOB, Tidy VA, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995 ; 13 : 547-52.
5. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990 ; 82 : 1539-45.
6. Touboul E, Buffat L, Lefranc JP, Blondon J, Deniaud E, Mammar H, et al. Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced non inflammatory breast cancer. Int J Radiat Oncol Biol Phys 1996 ; 34 : 1019-28.
7. Harris L, Swain SM. The role of primary chemotherapy in early breast cancer. Semin Oncol 1996 ; 23 (1 Suppl 2) : 31-42.
8. Jacquillat C, Weil M, Borel C, Auclerc G, de Maublanc MA, Housset M, et al. Regression tumorale comme facteur pronostique dans les cancers du sein. Butt Cancer 1991 ; 78 : 435-43.
9. Fischer B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997 ; 15 : 2483-93.
10. Brain EC, Misset JL, Rouesse J. Traitement médical d'induction et cancer du sein. Bull Cancer 1999 ; 86 : 745-52.
11. Bobin JY, Zinzindohoue C, Faure-Virelizier C, Joulai A, Khaled M. La chirurgie conservatrice des cancers du sein T2 > 3 cm, T3N0M0 après chimiothérapie d'induction. Bull Cancer 2001 ; 88 : 175-80.
12. Feldman LD, Hortobagyi GN, Budzar AU, Ames FC, Blumensschein GR. Pathologic assessment of response to induction chemotherapy in breast cancer. Breast Cancer Res Treat 1986 ; 46 : 2578-81.
13. Harms SE, Flaming DP, Hesley KL, Meiches MD, Jensen RA, Evan WP, et al. MR imaging of the breast with rotating delivery of excitation of resonance : clinical experience with pathologic correlation. Radiology 1993 ; 187 : 493-501.
14. Orel SG, Schnall MD, LiVolsi VA, Troupin RH. Suspicious breast lesions : MR imaging with radiologie pathologic correlation. Radiology 1994 ; 190 : 485-93.
15. Heywang-Kobrunner SH, Viehweg P, Heinig A, Kuchler CH. Contrast-enhanced MRI of the breast : accuracy, value, controversies, solutions. Eur J Radiol 1997 ; 24 : 94-108.
16. Boetes C, Strijk SP, Holland R, Barentsz JO, Van Der Sluis RF, Ruijs JH. False-negative MR imaging of malignant breast tumors. Eur Radiol 1997 ; 7 : 1231-4.
17. Pierga JY, Mouret E, Laurence V, Dieras V, Savigioni A, Beuzeboc P, et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. The role of clinical reponse. Eur J Cancer 2003 ; 39 : 1089-96.
18. Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, et al. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients trated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2002 ; 53 : 880-8.
19. Cure H, Charrier S, Ferriere JP, Van Praagh I, Assier I, Feillet V, et al. Chimiothérapie de première ligne dans les cancers du sein opérables : résultats de 3 protocoles. Bull Cancer 1997 ; 84 : 31-4.
20. Folkman J. Angiogenesis and breast cancer. J Clin Oncol 1994 ; 12 : 441-3.
21. Frouge C, Guinebretière JM, Contesso G, Di Paola R, Blery M. Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis. Investig Radiol 1994 ; 29 : 1043-9.
22. Tofts PS, Berkowitz B, Schnall D. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 1995 ; 33 : 564-8.
23. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis, correlation in invasive breast carcinoma. N Engl J Med 1991 ; 324 : 1-8.
24. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis : a new signifiant and independent prognosis indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992 ; 84 : 1875-87.
25. Merchanr TE, Obertop H, de Graaf PW. Advantages of magnetic resonance imaging in breast surgery treatment planning. Breast Cancer Res Treat 1993 ; 25 : 257-64.
26. Boetes C, Mus RD, Holland R, Barentsz JO, Strijk SP, Wobbes T, et al. Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology 1995 ; 197 : 743-7.
27. Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat 2002 ; 72 : 145-52.
28. Buthiau D, Rixe O, Nizri D, Piette JC, Khayat D. Cancer du sein : rôle de l'IRM dans le suivi des cas traités. Bull Acad Natl Med 1995 ; 179 : 693-705 Discussion : 705-6.
29. Abraham DC, Jones RC, Cheek JH, Peters GN, Knox SM, Grant MD, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996 ; 78 : 91-100.
30. Gilles R, Guinebretière JM, Toussaint C, Spielman M, Rietjens M, Petit JY, et al. Locally advanced breast cancer : contrast-enhanced-subtraction MR imaging of response to preoperative chemotherapy. Radiology 1994 ; 191 : 633-8.
31. Cocquyt VF, Villeirs GM, Blondeel PHN, Depypere HT, Mortiet MM, Serreyn RF, et al. Assessment of response to preoperative chemotherapy in patients with stage II and III breast cancer : the value of MRI. Breast 2002 ; 11 : 306-15.
32. Cocquyt VF, Blondeel PN, Depypere HT, Praet MM, Schelfhout VR, Silva OE, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 2003 ; 29 : 361-7.
33. Rodenko GN, Harms SE, Pruneda JM, Farrell RS, Evans WP, Copit DS, et al. MR imaging in the management before surgery of lobular carcinoma of the breast : correlation with pathology. Am J Roentgenol 1996 ; 167 : 1415-9.
34. Rieber A, Zeitler H, Rosenthal H, Gorich J, Kreienberg R, Brambs HJ, et al. MRI of breast cancer : influence of chemotherapy on sensitivity. Br J Radiol 1997 ; 70 : 452-8.
35. Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kühn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 2002 ; 12 : 1711-9.
36. Kedar RP, Cosgrove DO, McCready VR, Bamber JC, Carter ER. Micro-bubble contrast agent for color Doppler US: effect on breast masses. Work in progress. Radiology 1996 ; 198 : 679-86.
37. Schelling M, Avril N, Nahrig, Kuhn W, Romer W, Sattler D, et al. Positron emission tomography using [18F]-Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000 ; 18 : 1689-95.
38. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m] - sestamibi scintimammography. Cancer 1999 ; 85 : 2410-23.
39. Van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L, et al. Preoperative chemotherapy in primary operable breast cancer : results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001 ; 19 : 4224-37.
40. Fischer ER, Wang J, Bryant J, Fischer B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy : findings from the National Surgical Adjuvant Breast and Bowel protocol NSABP B-18. Cancer 2002 ; 95 : 681-95.
41. Therasse P, Arbuck SG, Eisenhauet EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the reponse to treatment in solid tumors. J Natl Cancer Inst 2000 ; 92 : 205-16.